SiaQuant Unveils Serum α2,3/α2,6 Sialylation Heterogeneities and Predicts Neoadjuvant Chemotherapy Response in Locally Advanced Cervical Cancer
Analytical Chemistry · 2025
DOI: 10.1021/acs.analchem.4c04952 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2025. Verfasst von Xiaoxiao Feng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Liver Cancer Institute of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Sialic Acids, N-Acetylneuraminic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Sialylation significantly influences tumor progression, invasion, and metastasis. Accurately characterizing sialylated N-glycopeptides (SGPs), particularly the linkage-specific analysis of α2,3,α2,6 sialic acids, remains a challenging yet crucial task in glycoproteomics. Notably, to date, there is a notable lack of detailed studies on α2,3/α2,6 sialylation in serum. Here, we present SiaQuant, an integrated strategy that employs liquid chromatography-ion mobility-tandem mass spectrometry (LC-IM-MS/MS), capitalizing on the distinctive separation of characteristic isomeric glycan fragments in ion mobility to accurately analyze serum α2,3/α2,6 sialylation patterns. It first provides proteome-wide insights into α2,3/α2,6 sialylation in serum, revealing three-dimensional heterogeneities across N-glycans, N-glycosites, and N-glycoproteins. Additionally, SiaQuant identifies potential candidate biomarkers for neoadjuvant chemotherapy (NACT) response in locally advanced cervical cancer (LACC), where the elevated level of α2,3/α2,6 sialylation was found to be associated with NACT resistance. In summary, SiaQuant offers the most comprehensive site- and linkage-specific N-glycosylation profiling of serum and shows great potential in clinical usage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Liver Cancer Institute of Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
- Department of Chemistry & NHC Key Laboratory of Glycoconjugates Research, Fudan University, Shanghai 200032, China.
- Department of Obstetrics and Gynecology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China.
- Waters Technologies, Shanghai 200233, China.
ORCID-Profile: Haojie Lu
Förderung
- National Key Research and Development Program of China
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Feng, X., Li, J., Li, C., Wang, J., Liang, Y., Fu, B., Sun, Z., Yao, J., He, J., Nie, A., Wei, L., Feng, W., & Lu, H. (2025). SiaQuant Unveils Serum α2,3/α2,6 Sialylation Heterogeneities and Predicts Neoadjuvant Chemotherapy Response in Locally Advanced Cervical Cancer. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.4c04952
Vancouver
Feng X, Li J, Li C, Wang J, Liang Y, Fu B, et al. SiaQuant Unveils Serum α2,3/α2,6 Sialylation Heterogeneities and Predicts Neoadjuvant Chemotherapy Response in Locally Advanced Cervical Cancer. Analytical Chemistry. 2025. doi:10.1021/acs.analchem.4c04952
BibTeX
@article{Feng2025,
author = {Feng, Xiaoxiao and Li, Jing and Li, Chong and Wang, Jun and Liang, Yuying and Fu, Bin and Sun, Zhenyu and Yao, Jun and He, Juan and Nie, Aiying and Wei, Liming and Feng, Weiwei and Lu, Haojie},
title = {SiaQuant Unveils Serum α2,3/α2,6 Sialylation Heterogeneities and Predicts Neoadjuvant Chemotherapy Response in Locally Advanced Cervical Cancer},
journal = {Analytical Chemistry},
year = {2025},
doi = {10.1021/acs.analchem.4c04952}
}
EUVIMED